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Abstract
Background: The purpose of our research was to determine the prognostic impact and clinicopathological feature
of c-MYC and β-catenin overexpression in colorectal cancer (CRC) patients.
Methods: Using immunohistochemistry (IHC), we measured the c-MYC and β-catenin expression in 367 consecutive
CRC patients retrospectively (cohort 1). Also, c-MYC expression was measured by mRNA in situ hybridization. Moreover,
to analyze regional heterogeneity, three sites of CRC including the primary, distant and lymph node metastasis were
evaluated in 176 advanced CRC patients (cohort 2).
Results: In cohort 1, c-MYC protein and mRNA overexpression and ß-catenin nuclear expression were found in
201 (54.8 %), 241 (65.7 %) and 221 (60.2 %) of 367 patients, respectively, each of which was associated with
improved prognosis (P = 0.011, P = 0.012 and P = 0.033, respectively). Moreover, co-expression of c-MYC and ß-
catenin was significantly correlated with longer survival by univariate (P = 0.012) and multivariate (P = 0.048)
studies. Overexpression of c-MYC protein was associated with mRNA overexpression (ρ, 0.479; P < 0.001) and
nuclear ß-catenin expression (ρ, 0.282; P < 0.001). Expression of c-MYC and ß-catenin was heterogeneous
depending on location in advanced CRC patients (cohort 2). Nevertheless, both c-MYC and ß-catenin expression
in primary cancer were significantly correlated with improved survival in univariate (P = 0.001) and multivariate
(P = 0.002) analyses. c-MYC and ß-catenin expression of lymph node or distant metastatic tumor was not
significantly correlated with patients’ prognosis (P > 0.05).
Conclusions: Co-expression of c-MYC and ß-catenin was independently correlated with favorable prognosis in
CRC patient. We concluded that the expression of c-MYC and ß-catenin might be useful predicting indicator of
CRC patient’s prognosis.
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Background
The c-MYC protein encode by c-MYC gene, acts as
transcription factor for variable cellular function in-
cluding proliferation, differentiation, metabolism, sur-
vival, and apoptosis [1, 2]. The c-MYC gene can
promote tumorigenesis in various malignant tumors
[3, 4] and mediate the critical role in the colorectal
cancer (CRC) progression [5, 6]. Deregulation of c-
MYC is a consequence of mutations in APC, a central
hub in early colorectal carcinogenesis [7].
c-MYC gene amplification, translocation, and alter-
ation of regulatory molecules are major causes of c-
MYC protein overexpression [8, 9]. Previously, other
group indicated that c-MYC amplification and overex-
pression was showed in approximately 10 and 70 % in
CRC, respectively [10]. These studies have deduced that
overexpression of c-MYC is controlled by mechanisms
other than gene amplification [10]. In recent years, it has
been evident that the mechanism of c-MYC
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overexpression is not restricted to genetic alterations,
such as amplification or translocation, but can also
occur as a consequence of abnormalities in regulatory
molecules [11]; in CRC, ß-catenin is one such regulatory
molecule. It is now well established that APC gene mu-
tation, a key driver of adenoma-carcinoma transition,
often leads to altered ß-catenin regulation via the well-
studied Wnt signaling pathway [12–14]. Regulation of
this pathway occurred while changing in nuclear ß-ca-
tenin protein levels. A destruction complex maintains a
low cytoplasmic concentration of ß-catenin when the
Wnt signaling pathway is inactivated. On the contrary,
the destruction complex degrades and ß-catenin in-
creases in the cytoplasm, leading to its migration to the
nucleus, where it work like a transcriptional factor for c-
MYC and cyclin D1 [15, 16]. Recent studies reported
CRCs with marked WNT and c-MYC signaling activa-
tion as a distinct molecular subtype by gene expression-
based CRC classifications, which was associated with
relatively better prognosis [17, 18]. It suggests that CRCs
with activated c-MYC via Wnt signaling pathway have
distinct clinicopathologic characteristics, but it has not
been confirmed.
Nevertheless, there were a few researches that reported
clinicopathological impact of c-MYC and ß-catenin status
in CRC. Their prognostic value for CRC patients remains
debatable. A recent study reported that c-MYC protein
overexpression obtained by immunohistochemistry (IHC)
was significantly correlated with better survival of CRC
patients [19]. In contrast, other researchers conducted
a meta-analysis showing that the accumulation of nu-
clear ß-catenin could be a biomarker for advanced stage
and worse survival of CRC [20]. However, the correl-
ation between immunohistochemical nuclear ß-catenin
expression and patient prognosis is quite controversial.
Consequently, it is necessary to further evaluate c-MYC
and ß-catenin expression to reach a conclusion about
their prognostic value.
Recently, the systemic chemotherapy in CRC has made
a remarkable development, and targeted therapy has
been used to increase survival in advanced CRC pa-
tients [21]. However, targeted therapy has no effect in
some CRC patients, despite presenting positivity for
target-therapy specific molecular examination [22]. Sev-
eral researchers have demonstrated that CRC shows a
regional heterogeneity in KRAS, EGFR, and BRAF mu-
tation, thus tumor heterogeneity may explain this dis-
crepancy between molecular alteration and responses
of targeted therapy [23–25]. Therefore, molecular alter-
ations between the metastatic and primary lesions need
to be discovered to enhance the treatment effect of
metastatic CRCs.
The aim of our research was to evaluate the clinical
implication of c-MYC and ß-catenin in CRC and
evaluate their heterogeneity in primary and distant
metastatic tumors. We also analyzed the association be-
tween c-MYC and ß-catenin status.
Methods
Collection of samples
A total of 543 CRC cases of this study had been col-
lected in our previous study [26]. To investigate the clin-
icopathological significance of c-MYC and ß-catenin
expression, we collected 367 consecutive CRC patients
who underwent surgery between 2005 and 2006 at
Seoul National University Bundang Hospital (cohort 1).
Additionally, to evaluate the locational heterogeneity of
c-MYC and ß-catenin expression, we collected syn-
chronous or metachronous metastatic 176 CRC pa-
tients with who had received surgery between 2003 and
2004, as well as between 2007 and 2009 excluding any
patient already enrolled in cohort 1 (cohort 2). Patholo-
gists K.S.L and H.S.L reviewed all the cases. Cancer
stage was determined from the American Joint Committee
on Cancer (AJCC) 7th edition. Clinical and pathologic in-
formation was acquired from hospital medical records in-
cluding patient’ outcome and survival.
Tissue array method
Tissue microarray (TMA) was constructed with represen-
tative lesions of the donor formalin-fixed paraffin-
embedded (FFPE) CRC tissues as previously described [27].
Immunohistochemistry
c-MYC IHC analysis was performed using an antibody
against c-MYC (clone Y69, catalog ab32072, Abcam,
Burlingame, CA, USA). ß-catenin IHC used a com-
mercially available antibody against ß-catenin (clone
CAT-5H10, Invitrogen, Camarillo, CA, USA). The
staining process was performed using an automated
immunostainer (BenchMark XT, Ventana Medical Sys-
tems), according to the manufacturer’s recommenda-
tions. Normal colonic mucosa cells were considered as
internal negative controls. Normal mucosa was nega-
tive for c-MYC nuclear immunostaining. ß-catenin
was negative in inflammatory cells, but expressed in
colonic epithelium in three patterns: membrane, cyto-
plasm, and nucleus. We only found ß-catenin nuclear
expression in malignant cells. For statistical analysis,
c-MYC and ß-catenin immunostaining were regarded
as positive when they were expressed in more than 10 %
of neoplastic nucleus in any intensity (Fig. 1) [19, 28].
Negative controls were obtained omitting the primary
antibody for each immunostaining.
mRNA in situ hybridization
For the detection of c-MYC mRNA transcripts, the
RNAscope 2.0 HD detection kit (Advanced Cell
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Diagnostics, Hayward, CA, USA) was used according
to the manufacturer’s protocols. The experimental
data was interpreted according to the manual in the
RNAscope FFPE assay kit: no staining or less than 1
dot/cell at 40× objective view (score of 0); staining in
1–3 dots/cell visible at 20–40× objective view (score
of 1); staining in 4–10 dots/cell with no or very few
dot clusters visible at 20–40× objective view (score
of 2); staining in >10 dots/cell with less than 10 % of
positive cells having dot clusters visible at 20× ob-
jective view (score of 3); staining in >10 dots/cell
with more than 10 % of positive cells having dot
clusters visible at 20× objective view (score of 4). A
score of 2–4 indicates c-MYC mRNA overexpression
(Fig. 1). UBC (ubiquitin C) and dapB (a bacterial
gene) were used for positive and negative controls.
Tissues were regarded as appropriate when the UBC
mRNA signals were visible without difficulty at 10×
magnification and the dapB signal was not visible.
Microsatellite instability
Microsatellite instability (MSI) examination using frag-
mentation assay of ABI-3130xl with five microsatellite
markers (BAT-26, BAT-25, D5S346, D17S250, and
D2S123) were analyzed according to the instruction
demonstrated previously [29]. MSI examination was
evaluated in available 519 cases.
Statistical analyses
All statistical analysis was performed with the SPSS
version 21 (IBM, Armonk, NY, USA) software. The
Chi-square test or Fisher’s exact test was used for
evaluating the correlation between clinicopathological
characteristics and c-MYC and ß-catenin expression.
The Pearson correlation coefficient was used for ana-
lyzing comparison of detection methods. The Kaplan-
Meier method with the log-rank test and multivariate
regression were performed to assess survival difference.
The survival results were determined with hazard ratio
(HR) and its 95 % confidence interval (CI). P < 0.05 was
considered statistically significant.
Results
Clinicopathological impacts of c-MYC and ß-catenin
expression in consecutive CRC patients
In 367 patients (cohort 1), a c-MYC mRNA in situ
hybridization score of 0 was observed in 34 (9.3 %), a
score of 1 in 92 (25.1 %), a score of 2 in 123 (33.5 %), a
score of 3 in 93 (25.3 %), and a score of 4 in 25 (6.8 %).
Consequentially, overexpression of c-MYC mRNA (a
score of 2–4) was observed in 241 patients (65.7 %). c-
MYC protein overexpression was observed in 201
(54.8 %), and ß-catenin nuclear overexpression was ob-
served in 221 (60.2 %) patients.
Table 1 demonstrates the correlations between c-MYC
and ß-catenin overexpression and clinicopathological
Fig. 1 Representative figures of c-MYC status detected by in situ hybridization (a and d) and immunohistochemistry (IHC; b and e), and of ß-catenin
expression by IHC (c and f), in colorectal cancer patients. a Score 4 mRNA (40×); b c-MYC overexpression (40×); c Nuclear ß-catenin expression (40×);
d Score 0 mRNA (40×); e No c-MYC expression (40×); f Membranous ß-catenin expression (40×)
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parameters. c-MYC protein overexpression was associ-
ated with non-aggressive characteristics, including early
pT stage, low-grade differentiation, absence of perineural
invasion, and smaller tumor size (P < 0.001, P = 0.007, P
= 0.025 and P < 0.001, respectively). In addition, c-MYC
protein overexpression was associated with a tumor lo-
cation in the recto-sigmoid colon. Increased levels of the
c-MYC mRNA transcript were associated with microsat-
ellite stable CRC (P = 0.019), located in the sigmoid
colon and rectum, and with less aggressive features,
similarly to c-MYC protein overexpression. Likewise, ß-
catenin nuclear expression was frequently detected in
tumors of the recto-sigmoid colon, of low-grade differ-
entiation (P = 0.006), of small size (P = 0.007) and micro-
satellite stable CRC (P < 0.001).
Correlation between c-MYC and ß-catenin expression in
consecutive CRC patients
In cohort 1, c-MYC protein overexpression was corre-
lated with mRNA overexpression (ρ, 0.479; P < 0.001),
which was classified as moderate correlation [30]. ß-ca-
tenin nuclear expression was weakly associated with c-
MYC protein overexpression and mRNA overexpression
(ρ, 0.282; P < 0.001 and 0.211; P < 0.001, respectively).
Locational heterogeneity of c-MYC and ß-catenin status
For analysis the locational heterogeneity of c-MYC and
ß-catenin expression, we investigated cancer from three
lesion, including the primary, distant and lymph node
metastasis (cohort 2). All 176 cases had distant meta-
static lesions. Among them, 142 cases had lymph node
metastases, even though we dissected more than 20
lymph nodes in all CRC patients respectively. The clini-
copathological features of the cohort 2 are indicated in
Table 2 as previously reported [31]. Not every cohort 2
patients are stage IV due to metachronous metastasis
which develops consequently after treatment of the first
primary tumor. The distant metastatic sites were de-
scribed below: liver in 82 cases (46.6 %), lung in 37
cases (21.0 %), peritoneal seeding in 38 cases (21.6 %),
distant lymph nodes in 3 cases (1.7 %), and ovary in 16
cases (9.0 %).
In the primary tumors of cohort 2, c-MYC protein
overexpression, mRNA overexpression and nuclear ß-ca-
tenin expression was detected in 57.6 % (102 out of
176), 77.4 % (137 out of 176) and 61.0 % (108 out of
176) of tumors, respectively. In distant metastatic tu-
mors, c-MYC protein overexpression, mRNA overex-
pression, and nuclear ß-catenin expression was detected
in 37.3 % (66 out of 176), 74.6 % (132 out of 176) and
47.5 % (84 out of 176) of tumors, respectively. In 142
lymph node metastases, we performed c-MYC and ß-ca-
tenin analysis in 111 cases which paraffin blocks were
available. c-MYC protein overexpression, mRNA
overexpression, and nuclear ß-catenin expression was
detected in 66.7 % (74 out of 111), 77.5 % (86 out of
111) and 58.6 % (65 out of 111) of tumors, respectively.
The locational heterogeneity of c-MYC and ß-catenin
status is demonstrated in Table 3. Discordance of c-
MYC protein overexpression between the primary and
distant metastatic cancer was detected in 45.5 % (80 out
of 176) of cases, and discordance between the primary
and lymph node metastatic cancer was observed in
31.5 % (35 out of 111) of cases. Discordance of c-MYC
mRNA overexpression between the primary and distant
metastatic cancer was detected in 25.6 % (45 out of 176)
of cases, and discordance between the primary and
lymph node metastatic cancer was observed in 30.6 %
(34 out of 111) of cases. Discordance of nuclear ß-ca-
tenin expression between the primary and distant meta-
static cancer was detected in 29.0 % (51 out of 176) of
cases, while discordance between the primary and lymph
node metastatic cancer was observed in 26.1 % (29 out
of 111) of cases. Consequently, locational heterogeneity
of c-MYC and ß-catenin expression was frequently seen
in advanced CRC.
Prognostic impact of c-MYC and ß-catenin expression in
CRC
All CRC patients of our study were successfully included
survival analysis (Fig. 2 and Additional file 1: Table S1).
In the consecutive cohort (cohort 1), the median follow-
up was 55 months (1–85 months) as previous reported
[26]. c-MYC protein overexpression, mRNA overexpres-
sion and nuclear ß-catenin expression were significantly
correlated with an improved survival in Kaplan-Meier
analysis (P = 0.011, P = 0.012 and P = 0.033, respectively).
When prognostic analysis was performed using the com-
bined status of c-MYC and ß-catenin expression, positivity
for both proteins (c-MYC/ß-catenin: +/+) was observed
84/367 (22.9 %) cases and was significantly correlated with
an improved survival (P = 0.012). We additionally investi-
gated the c-MYC protein overexpression by density of
staining - scoring each tumor as low (0–1) to high (2–3)
in cohort 1. The percentage of positive neoplastic cells
was correlated with density of staining of neoplastic cells
(ρ, 0.789; P < 0.001), which was categorized as strong cor-
relation [30]. However, the staining density of c-MYC pro-
tein was not significantly correlated with patients’
prognosis (P = 0.070, Additional file 2: Figure S1).
In the cohort with metastases (cohort 2), the median
follow-up was 43 months (1–105 months), as previous
reported [31]. In the primary cancer, Kaplan-Meier ana-
lysis showed that c-MYC protein overexpression and nu-
clear ß-catenin expression were significantly correlated
with improved prognosis (P = 0.005 and P = 0.007, re-
spectively), but mRNA overexpression was not (P =
0.258). Co-expression of c-MYC and ß-catenin (c-MYC/
Lee et al. BMC Cancer  (2016) 16:730 Page 4 of 12
Table 1 The association between clinicopathological parameters and expression of c-MYC and ß-catenin in 367 CRC patients (cohort1)
Total c-Myc IHC P-Value c-Myc RNA ISH (score) P-Value ß-catenin IHC (%) P-Value
Negative Positive Negative Positive Negative Positive
Age
mean 64.2 64.6 63.9 0.537 63.4 64.7 0.334 64.1 63.7 0.257
Sex
male 205 89 (43.4 %) 116 (56.6 %) 0.431 72 (35.1 %) 133 (64.9 %) 0.720 82 (40.0 %) 123 (60.0 %) 0.924
female 162 77 (47.5 %) 85 (52.5 %) 54 (33.3 %) 108 (66.7 %) 64 (39.5 %) 98 (60.5 %)
Location
cecum 13 12 (92.3 %) 1 (7.7 %) 0.002 12 (92.3 %) 1 (7.7 %) 0.039 11 (84.6 %) 2 (15.4 %) 0.103
ascending colon 55 39 (70.9 %) 16 (29.1 %) 37 (67.3 %) 18 (32.7 %) 36 (65.5 %) 19 (34.5 %)
hepatic flexure 22 14 (63.6 %) 8 (36.4 %) 17 (77.3 %) 5 (22.7 %) 14 (63.6 %) 8 (36.4 %)
transverse colon 16 10 (62.5 %) 6 (37.5 %) 11 (68.8 %) 5 (31.3 %) 11 (68.8 %) 5 (31.3 %)
splenic flexure 6 5 (83.3 %) 1 (16.7 %) 4 (66.7 %) 2 (33.3 %) 4 (66.7 %) 2 (33.3 %)
descending colon 18 15 (83.3 %) 3 (16.7 %) 15 (83.3 %) 3 (16.7 %) 13 (72.2 %) 5 (27.8 %)
sigmoid colon 114 53 (46.5 %) 61 (53.5 %) 64 (56.1 %) 50 (43.9 %) 62 (54.4 %) 52 (45.6 %)
rectum 123 71 (57.7 %) 52 (42.3 %) 89 (72.4 %) 34 (27.6 %) 61 (49.6 %) 62 (50.4 %)
pT stage
0–2 58 14 (24.1 %) 44 (75.9 %) <0.001 14 (24.1 %) 44 (75.9 %) 0.075 17 (29.3 %) 41 (70.7 %) 0.076
3–4 309 152 (49.2 %) 157 (50.8 %) 112 (36.2 %) 197 (63.8 %) 129 (41.7 %) 180 (58.3 %)
Differentiation
LG 331 142 (42.9 %) 189 (57.1 %) 0.007 101 (30.5 %) 230 (69.5 %) <0.001 124 (37.5 %) 207 (62.5 %) 0.006
HG 36 24 (66.7 %) 12 (33.3 %) 25 (69.4 %) 11 (30.6 %) 22 (61.1 %) 14 (38.9 %)
LN metastasis
absent 168 67 (39.9 %) 101 (60.1 %) 0.058 58 (34.5 %) 110 (65.5 %) 0.943 63 (37.5 %) 105 (62.5 %) 0.412
present 199 99 (49.7 %) 100 (50.3 %) 68 (34.2 %) 131 (65.8 %) 83 (41.7 %) 116 (58.3 %)
Lymphatic invasion
absent 158 63 (39.9 %) 95 (60.1 %) 0.073 51 (32.3 %) 107 (67.7 %) 0.471 61 (38.6 %) 97 (61.4 %) 0.689
present 209 103 (49.3 %) 106 (50.7 %) 75 (35.9 %) 134 (64.1 %) 85 (40.7 %) 124 (59.3 %)
Perineural invasion
absent 154 49 (31.8 %) 105 (68.2 %) 0.025 78 (30.7 %) 176 (69.3 %) 0.028 99 (39.0 %) 155 (61.0 %) 0.636
present 113 61 (54.0 %) 52 (46.0 %) 48 (42.5 %) 65 (57.5 %) 47 (41.6 %) 66 (58.4 %)
Venous invasion
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present 71 33 (46.5 %) 38 (53.5 %) 25 (35.2 %) 46 (64.8 %) 25 (35.2 %) 46 (64.8 %)
Tumor border
expanding 60 25 (41.7 %) 35 (58.3 %) 0.544 27 (45.0 %) 33 (55.0 %) 0.057 24 (40.0 %) 36 (60.0 %) 0.970
infiltrative 307 141 (45.9) 166 (54.1 %) 99 (32.2 %) 208 (67.8 %) 122 (39.7 %) 185 (60.3 %)
Size (cm)
mean 5.3 5.8 4.8 <0.001 6.0 4.9 <0.001 5.6 5.0 0.007
Distant metastasis
absent 299 131 (43.8 %) 168 (56.2 %) 0.252 97 (32.4 %) 202 (67.6 %) 0.110 115 (38.5 %) 184 (61.5 %) 0.278
present 68 35 (51.5 %) 33 (48.5 %) 29 (42.6 %) 39 (57.4 %) 31 (45.6 %) 37 (54.4 %)
pTNM stage
I, II 162 64 (39.5 %) 98 (60.5 %) 0.050 55 (34.0 %) 107 (66.0 %) 0.891 59 (37.1 %) 100 (62.9 %) 0.399
III, IV 205 102 (49.8 %) 103 (50.2 %) 71 (34.6 %) 134 (65.4 %) 85 (41.5 %) 120 (58.5 %)
MSI status
MSS/MSI-L 323 141 (43.7 %) 182 (56.3 %) 0.490 105 (32.5 %) 218 (67.5 %) 0.019 177 (54.8 %) 146 (45.2 %) <0.001
MSI-H 32 16 (50.0 %) 16 (50.0 %) 17 (53.1 %) 15 (46.9 %) 28 (87.5 %) 4 (12.5 %)
Chemotherapy status
none 97 41 (42.3 %) 56 (57.7 %) <0.001 67 (69.1 %) 30 (30.9 %) 0.748 49 (50.5 %) 48 (49.5 %) 0.175
pre- 0 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
post- 269 177 (65.8 %) 92 (34.2 %) 181 (67.3 %) 88 (32.7 %) 162 (60.2 %) 107 (39.8 %)
Pre- and post- 1 1 (100.0 %) 0 (0.0 %) 1 (100.0 %) 0 (0.0 %) 1 (100.0 %) 0 (0.0 %)
P-values are calculated by using χ2-test or Fisher’s exact test












ß-catenin: +/+) also predicted better prognosis (P =
0.001). The c-MYC and ß-catenin expression status in
distant or lymph node metastatic cancer did not signifi-
cantly associated with patients’ survival (P > 0.05, data
not shown). The presence of locational heterogeneity of
c-MYC and ß-catenin expression was not associated
with survival (P > 0.05; data not shown). In addition, we
evaluated the Kaplan–Meier survival for MSI status,




Synchronous (n = 118) Metachronous (n = 58) P-Value
Sex male 96 56 (47.5 %) 40 (69.0 %) 0.006
female 80 62 (52.5 %) 18 (31.0 %)
Metastatic site liver 82 61 (52.1 %) 21 (36.2 %) <0.001
lung 37 10 (8.5 %) 27 (46.6 %)
peritoneal seeding 38 32 (26.5 %) 6 (10.3 %)
distant lymph node 3 2 (1.7 %) 1 (1.7 %)
ovary 16 13 (11.1 %) 3 (5.2 %)
Location of primary tumor appendix 1 1 (0.9 %) 0 (0.0 %) 0.293
cecum 7 7 (6.0 %) 0 (0.0 %)
ascending colon 17 14 (12.0 %) 3 (5.2 %)
hepatic flexure 13 9 (7.7 %) 4 (6.9 %)
transverse colon 9 7 (6.0 %) 2 (3.4 %)
splenic flexure 7 4 (3.4 %) 3 (5.2 %)
descending colon 8 6 (5.1 %) 2 (3.4 %)
sigmoid colon 50 28 (23.9 %) 22 (37.9 %)
rectum 64 42 (35.0 %) 22 (37.9 %)
T stage T1 1 1 (0.9 %) 0 (0.0 %) <0.001
T2 3 1 (0.9 %) 2 (3.4 %)
T3 107 60 (50.4 %) 47 (81.0 %)
T4 65 56 (47.9 %) 9 (15.5 %)
N stage N0 34 13 (11.1 %) 21 (36.2 %) <0.001
N1 62 37 (31.6 %) 25 (43.1 %)
N2 80 68 (57.3 %) 12 (20.7 %)
Stage I 2 0 (0.0 %) 2 (3.4 %) <0.001
II 18 0 (0.0 %) 18 (31.0 %)
III 45 8 (6.8 %) 37 (63.8 %)
IV 111 110 (93.2 %) 1 (1.7 %)
Differentiation low grade 158 104 (88.0 %) 54 (93.1 %) 0.299
high grade 18 14 (12.0 %) 4 (6.9 %)
Lymphatic invasion absent 62 38 (32.5 %) 24 (41.4 %) 0.247
present 114 80 (67.5 %) 34 (58.6 %)
Venous invasion absent 123 77 (65.0 %) 46 (79.3 %) 0.052
present 53 41 (35.0 %) 12 (20.7 %)
Perineural invasion absent 90 56 (47.9 %) 34 (58.6 %) 0.180
present 86 62 (52.1 %) 24 (41.4 %)
Tumor border expanding 13 6 (5.1 %) 7 (12.1 %) 0.099
infiltrative 163 112 (94.9 %) 51 (87.9 %)
P-values are calculated by using χ2-test or Fisher’s exact test
Abbreviations: T tumor; N lymph node
Lee et al. BMC Cancer  (2016) 16:730 Page 7 of 12
stage, chemotherapy status, site of primary cancer and
site of distant metastasis (Additional file 2: Figure S1).
The multivariate Cox’s proportional hazards regres-
sion model of c-MYC and ß-catenin expression was
described in Table 4, and indicated that co-expression
of c-MYC and ß-catenin was an independent prog-
nostic factor for better survival in both cohort 1 and
primary tumor of cohort 2 (P = 0.048 and P = 0.002,
respectively). However, individual analysis of c-MYC
protein overexpression, mRNA overexpression, and
nuclear ß-catenin expression did not independently
predict better prognosis.
Discussion
There were several studies on c-MYC status in various
malignancies. Some malignant tumors with c-MYC over-
expression including gastric carcinoma, esophageal squa-
mous cell carcinoma, and soft tissue leiomyosarcoma are
associated with poor survival [32–34]. Likewise, several
cancers with c-MYC gene amplification tend to be corre-
lated with poor survival [35–37]. Interestingly, c-MYC
mRNA overexpression in CRC was reported to be
correlated with improved survival [5], but this was
opposite result to previous other study [38]. Never-
theless, recent research indicated that immunohisto-
chemical c-MYC overexpression was significantly
associated with better prognosis of CRC patients in
univariate model, but not in multivariate model [19].
In addition, many studies have shown that ß-catenin
is crucial part of the Wnt signaling pathway in CRC
development [39]. Recently, a meta-analysis study
showed that nuclear overexpression of ß-catenin ap-
peared to be associated with progressive disease for
CRC patients [20]. However, prognostic value of nu-
clear overexpression of ß-catenin in CRC patients re-
mains controversial [40, 41].
In our study, overexpression of c-MYC protein in the
consecutive cohort was significantly correlated with an
improved prognosis in univariate model, but not in
multivariate model. The prognostic significance of nu-
clear ß-catenin expression is similar to that of c-MYC
protein overexpression. We performed a combined ana-
lysis of c-MYC and ß-catenin expression because these
proteins are closely related. Astonishingly, co-expression
of c-MYC and ß-catenin correlated with an improved
prognosis by univariate and multivariate analysis.
Although the advanced cohort was mainly consisted of
stage IV CRC patients (111 cases; 63.1 %), co-
expression of c-MYC and ß-catenin was independently
predicted favorable prognosis. Furthermore, overex-
pression of c-MYC and ß-catenin—except c-MYC
mRNA—in the advanced cohort was significantly corre-
lated with better prognosis using a univariate model.
Consequently, co-expression of c-MYC and ß-catenin
determined by IHC might be of use in the assessment
of CRC patients.
We also demonstrated that ß-catenin nuclear expres-
sion significantly associated with its target molecule c-
MYC in CRC patients (ρ, 0.282; P < 0.001). Overexpres-
sion of c-MYC can be caused by complex regulatory
pathways and multiple communications with other fac-
tors, rather than just c-MYC gene alterations [42]. An
example of such a mechanism is signaling via ß-catenin,
a c-MYC regulator whose nuclear accumulation is corre-
lated with c-MYC overexpression [7, 43]. ß-catenin in-
creases in the cytoplasm and undergoes translocation to
the nucleus, where it plays as a transcription factor for
target genes such as c-MYC [16]. These processes ex-
plain that nuclear expression of ß-catenin is partly
responsible for c-MYC overexpression. As a result, co-
expression of c-MYC and ß-catenin can be considered
as c-MYC overexpression via ß-catenin in CRC. The
APC gene mutation is the initial step of CRC oncogen-
esis [44] and often lead to deregulation of ß-catenin
[45]. Thus, ß-catenin-dependent c-MYC overexpression
can be suggested in early colorectal carcinogenesis. In
addition, recent studies suggested that high-level nuclear
β-catenin in CRC was significantly correlated with high
Ki67 expression [46], and indicated that tumor prolifera-
tive activity was inversely related to CRC aggressiveness
and metastases [47, 48]. For this reason, c-MYC overex-
pression via ß-catenin might have an influence on im-
proved prognosis of CRC patients. Moreover, E Melo et
al. reported that CpG island methylation interrupts sev-
eral Wnt target genes, including ASCL2 and LGR5 dur-
ing CRC progression and promoter methylation of
Wnt target genes is a powerful predictive factor for
CRC relapse [16]. Therefore, silencing of ß-catenin/
Wnt pathway by methylation generates CRC progres-
sion and worse prognosis. It is noteworthy that our
Table 3 Heterogeneity of c-MYC and ß-catenin with respect to
tumor location in advanced CRC (cohort 2)
cMYC IHC Distant metastasis LN metastasis
Negative Positive Negative Positive
Primary Negative 52 (29.5 %) 22 (12.5 %) 23 (20.7 %) 21 (18.9 %)
Positive 58 (33.0 %) 44 (25.0 %) 14 (12.6 %) 53 (47.7 %)
cMYC mRNA ISH Distant metastasis LN metastasis
Negative Positive Negative Positive
Primary Negative 19 (10.8 %) 20 (11.4 %) 8 (7.2 %) 17 (15.3 %)
Positive 25 (14.2 %) 112 (63.6 %) 17 (15.3 %) 69 (62.2 %)
ß-catenin IHC Distant metastasis LN metastasis
Negative Positive Negative Positive
Primary Negative 55 (31.3 %) 14 (8.0 %) 30 (27.0 %) 13 (11.7 %)
Positive 37 (21.0 %) 70 (39.8 %) 16 (14.4 %) 52 (46.8 %)
Abbreviations: IHC immunohistochemistry, ISH in-situ hybridization
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Fig. 2 Kaplan–Meier survival curves illustrating the prognostic effects of c-MYC status in colorectal cancer. a-d Cohort 1; a c-MYC mRNA overexpression;
b c-MYC protein overexpression; c Nuclear ß-catenin expression; d Co-expression of c-MYC and ß-catenin; e-h Primary tumor of cohort 2; e c-MYC
mRNA overexpression; f c-MYC protein overexpression; g Nuclear ß-catenin expression; h Co-expression of c-MYC and ß-catenin
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Table 4 Multivariate Cox proportional hazard models for the predictors of overall survival
Factors Univariate survival analysis Multivariate survival analysis
HR (95 % CI) P value HR (95 % CI) P value
Cohort 1
co-expression of c-MYC and ß-catenin 0.482 (0.310–0.749) 0.012 0.629 (0.397–0.996) 0.048
Age 1.026 (1.008–1.045) 0.005 1.022 (1.004–1.040) 0.015
Size 1.244 (1.059–1.244) 0.001 1.049 (0.946–1.163) NS (0.362)
Histologic grade (high vs. low) 3.143 (1.904–5.188) <0.001 2.842 (1.608–5.023) <0.001
Stage (3/4 vs. 1/2) 6.151 (3.494–10.829) <0.001 2.942 (1.538–5.628) 0.001
Lymphatic invasion 3.661 (2.242–5.980) <0.001 1.338 (0.763–2.349) NS (0.310)
Perineural invasion 3.942 (2.648–5.870) <0.001 2.337 (1.487–3.673) <0.001
Venous invasion 3.985 (2.671–5.946) <0.001 2.163 (1.390–3.366) 0.001
c-MYC mRNA expression 0.599 (0.403–0.891) 0.011 0.703 (0.464–1.066) NS (0.097)
Age 1.026 (1.008–1.045) 0.005 1.024 (1.006–1.042) 0.008
Size 1.244 (1.059–1.244) 0.001 1.056 (0.953–1.169) NS (0.297)
Histologic grade (high vs. low) 3.143 (1.904–5.188) <0.001 2.785 (1.562–4.968) 0.001
Stage (3/4 vs. 1/2) 6.151 (3.494–10.829) <0.001 3.017 (1.574–5.782) 0.001
Lymphatic invasion 3.661 (2.242–5.980) <0.001 1.327 (0.756–2.330) NS (0.324)
Perineural invasion 3.942 (2.648–5.870) <0.001 2.438 (1.554–3.827) <0.001
Venous invasion 3.985 (2.671–5.946) <0.001 2.102 (1.356–3.259) 0.001
c-MYC protein expression 0.593 (0.400–0.880) 0.010 0.751 (0.498–1.132) NS (0.171)
Age 1.026 (1.008–1.045) 0.005 1.023 (1.005–1.041) 0.012
Size 1.244 (1.059–1.244) 0.001 1.054 (0.951–1.169) NS (0.317)
Histologic grade (high vs. low) 3.143 (1.904–5.188) <0.001 2.967 (1.681–5.236) <0.001
Stage (3/4 vs. 1/2) 6.151 (3.494–10.829) <0.001 2.959 (1.549–5.653) 0.001
Lymphatic invasion 3.661 (2.242–5.980) <0.001 1.344 (0.766–2.356) NS (0.303)
Perineural invasion 3.942 (2.648–5.870) <0.001 2.388 (1.522–3.746) <0.001
Venous invasion 3.985 (2.671–5.946) <0.001 2.105 (1.356–3.269) 0.001
ß-catenin protein expression 0.666 (0.449–0.986) 0.042 0.740 (0.497–1.101) NS (0.138)
Age 1.026 (1.008–1.045) 0.005 1.023 (1.005–1.041) 0.012
Size 1.244 (1.059–1.244) 0.001 1.068 (0.966–1.180) NS (0.197)
Histologic grade (high vs. low) 3.143 (1.904–5.188) <0.001 2.897 (1.645–5.102) <0.001
Stage (3/4 vs. 1/2) 6.151 (3.494–10.829) <0.001 3.034 (1.587–5.801) 0.001
Lymphatic invasion 3.661 (2.242–5.980) <0.001 1.356 (0.771–2.383) NS (0.290)
Perineural invasion 3.942 (2.648–5.870) <0.001 2.367 (1.508–3.717) <0.001
Venous invasion 3.985 (2.671–5.946) <0.001 2.071 (1.331–3.224) 0.001
Primary tumor of cohort 2
co-expression of c-MYC and ß-catenin 0.430 (0.254–0.726) 0.001 0.440 (0.259–0.747) 0.002
Age 1.023 (1.001–1.045) 0.037 1.025 (1.004–1.047) 0.020
Stage (3/4 vs. 1/2) 7.894 (1.922–32.418) 0.004 5.731 (1.380–23.800) 0.016
Lymphatic invasion 2.480 (1.402–4.386) 0.002 1.712 (0.940–3.117) NS (0.079)
Perineural invasion 2.119 (1.313–3.421) 0.002 1.724 (1.049–2.831) 0.032
P-values are calculated by using χ2-test or Fisher’s exact test
Abbreviations: HR hazard ratio
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result adds clinical evidence to support these previous
studies [16–18, 46–48]. The lack of ß-catenin expres-
sion in CRC patients with presenting c-MYC overex-
pression shows a rather worse survival, presumably
because, in these patients, the c-MYC is controlled by
other regulatory factors. Future studies will be required
to dissect the different mechanisms of ß-catenin-medi-
ated c-MYC overexpression.
In the advanced cohort, regional heterogeneity of c-
MYC and ß-catenin expression was frequently observed
in advanced CRC. Nonetheless, c-MYC and ß-catenin
expression was associated with better prognosis in the
primary, not distant and lymph node metastatic cancer.
Consequently, when we evaluate prognosis with c-MYC
and ß-catenin, tissue from primary CRC should be used.
In daily practice for pathologists, metastatic cancer tis-
sue can only occasionally be obtained. Some re-
searchers suggest that regional heterogeneity should be
considered as a potential limitation to the evaluation
of prognostic and therapeutic value in tissue from
metastatic lesions [49, 50]. Therefore, the importance
of regional heterogeneity must be assessed in bio-
marker research.
Conclusions
Our study comprehensively evaluated the c-MYC and ß-
catenin status of CRC patients. Overexpression of c-
MYC protein, mRNA, and ß-catenin nuclear expression
were observed in 54.8, 65.7, and 60.2 % of consecutive
CRC patients, respectively. c-MYC protein overexpres-
sion was significantly correlated with mRNA overexpres-
sion and with ß-catenin nuclear expression. Interestingly,
co-expression of c-MYC and ß-catenin—in other words,
c-MYC overexpression via ß-catenin—was an independ-
ent improved prognostic factor in both the consecutive
and advanced cohort. These findings indicate that c-
MYC and ß-catenin IHC can be used as prognostic
marker of CRC patients. However, further investiga-
tions on the detailed mechanism of connection between
c-MYC and ß-catenin and its impact on patients’ out-
come in CRC are needed.
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